Hengrui's oral GLP-1 pill HRS-7535 hits 10.9% weight loss in China Phase 3
HARBOR-1 met its primary endpoint against placebo, positioning the oral small molecule among the first Phase 3 obesity readouts for this drug class in China.
Executive Summary
- A Phase 3 obesity trial of Hengrui Pharma's oral GLP-1 receptor agonist met its primary weight-loss endpoint against placebo, clearing the bar the study was designed to test.
- The result directly supports the sponsor's stated plan to file for regulatory approval in China, moving the program from clinical proof toward a submission.
- The same molecule is separately being tested outside China in a dose-finding study aimed at optimizing its profile before a broader global development push, so this result also seeds that parallel effort.
- The trial sits in a field of oral and injectable weight-loss mechanisms where most late-stage rivals differ in modality or target, leaving this program's direct precedent within its own class limited.
The result
HARBOR-1, a 556-patient Phase 3 trial registered as NCT06904105, tested HRS-7535 tablets against placebo in Chinese adults with a body mass index of at least 28, or at least 24 with a weight-related comorbidity such as hyperglycemia or hypertension. The trial's two co-primary endpoints were percentage change in body weight from baseline and the proportion of participants achieving at least 5% weight loss. Topline data announced July 7, 2026 showed mean weight loss of up to 10.9% at Week 44 and up to 11.1% at Week 50 on the highest studied dose, against 2.5% for placebo, meeting the primary endpoint. NCT06904105+1A Trial of HRS-7535 Tablets in Subjects With Overweight or ObesityNCT06904105Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical ...Jul 7, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
Safety and the trial's stake
Kailera Therapeutics' chief medical officer, Scott Wasserman, said the results "highlight the promise of oral small molecules as a treatment option for people living with obesity, with the potential to combine clinically meaningful weight loss with convenience, scalability, and accessibility". Safety findings were described as consistent with data generated to date, with no liver safety signal observed and adverse events dominated by mild-to-moderate gastrointestinal events. Because HRS-7535 is an oral small molecule rather than an injectable peptide, the trial's core stake was whether an oral GLP-1 agonist could approach the weight-loss magnitude of injectable comparators while offering the convenience of a pill; the double-digit percentage loss addresses that question directly. Kailera+1Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical ...Jul 7, 2026A Trial of HRS-7535 Tablets in Subjects With Overweight or ObesityNCT06904105
Regulatory path
Hengrui Pharma intends to submit New Drug Applications for HRS-7535 in both obesity and type 2 diabetes in China, based on HARBOR-1 and a companion Phase 3 diabetes trial, OUTSTAND-2 (NCT06589765), which separately showed HbA1c reductions of 1.50 to 1.68 percentage points across doses. The molecule was developed by Hengrui and licensed to Kailera Therapeutics outside Greater China in 2024, and more than 2,000 patients have now been dosed with it in Chinese trials. Kailera is running its own global Phase 2 trial of the same molecule, called KAI-7535, in the United States and Australia, testing a wider dose range, a lower 15 mg starting dose, and a more gradual titration schedule across four 80-patient cohorts, with data expected in 2027. KaileraKailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical ...Jul 7, 2026
Where it sits competitively
Among industry-sponsored trials pairing the GLP-1 receptor target with obesity or overweight, HARBOR-1 is the only one at Phase 3, with peer programs such as Gan & Lee Pharmaceuticals' GZR18 running in the same indication in China at Phase 3 but against a different target profile. Late-stage oral GLP-1 competitors in the broader obesity field, including Eli Lilly's orforglipron, AstraZeneca's elecoglipron, and Structure Therapeutics' aleniglipron, are also small molecules but target different mechanisms within the incretin receptor family, and none has yet disclosed a matching Phase 3 obesity result in the record reviewed here. That leaves HRS-7535's China result without a direct same-target Phase 3 precedent to benchmark against, positioning it as an early data point for oral GLP-1 agonism in this population rather than a replication of an established result.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.